1. Home
  2. CISO vs GLTO Comparison

CISO vs GLTO Comparison

Compare CISO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CISO Global Inc.

CISO

CISO Global Inc.

HOLD

Current Price

$0.46

Market Cap

24.5M

Sector

Technology

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$31.52

Market Cap

23.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISO
GLTO
Founded
2015
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.5M
23.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CISO
GLTO
Price
$0.46
$31.52
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
817.2K
207.8K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,743,266.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$2.01
52 Week High
$3.84
$33.60

Technical Indicators

Market Signals
Indicator
CISO
GLTO
Relative Strength Index (RSI) 30.22 70.74
Support Level $0.46 $25.60
Resistance Level $0.60 $32.20
Average True Range (ATR) 0.06 3.02
MACD 0.01 0.76
Stochastic Oscillator 3.07 91.79

Price Performance

Historical Comparison
CISO
GLTO

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: